Scholar Rock Holding (SRRK) stock

Rare disease medicines , market cap $5.4B

Medicines for rare neuromuscular diseases

Market cap $5.4B

$42.91

-2.26%

After-hours $43.07 +0.37%

As of 6:57 PM ET after-hours, delayed 15+ min · Live for Pro members

Quality Score

Below Average

In its industry

#124of 291

Biotech

Checks firing

1of 14

Trending down

From 52-week high

-30.5%

Below the 200-day

SRRK's Quality Score fell 1 point on Mon, Nov 2, to 0.

Follow SRRK's trial news. Pro members can get an alert when Scholar Rock Holding files news, and see its trials, share raises, and its CEO's filings.

Get an alert when SRRK files news on its trialsSee it live, free until Wednesday morning. No account. No card. Then keep going with a free account.

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

NextLate 2026“…study evaluating SRK-439 in healthy volunteers is progressing well with topline data anticipated in late 2026…”Trial data · SEC filing · Aug 6

Cash$492M, about 6 quarters at the last year's spendingOn Jun 30 · raised money since, not counted · the company says “into 2027”

Why is SRRK up?

Up 281% over three years while the S&P 500 rose 89%.

Its filed figures weakened while the shares beat the market.

Sources: Price history, Oct 30, 2026; Quarterly reports, Jun 30, 2026

The other side, how the business stands, the timeline, and its peers, for Pro members.

Key facts on SRRK

Key facts on SRRK
Holding it back	A $409M loss wider than $316M a year earlier
Latest filing	10-Q, Aug 6 Filed its quarterly report (10-Q) for the quarter to Jun 30, 2026

1 more reason behind SRRK's 0, free with an account →3 more reasons behind SRRK's 0, for Pro members.

Cash$492M, about 6 quarters at the last year's spendingOn Jun 30 · raised money since, not counted · the company says “into 2027”

SRRK catalysts

Coming up

After its last 4 reports it closed +8.7% on average, higher 3 of 4 times.

3 past catalysts since 2026, with sizes and sources, for Pro members.Get in free →

What's next for SRRK, and how long its cash lasts

Next step the company has named

Late 2026“A Phase 1 study evaluating SRK-439 in healthy volunteers is progressing well with topline data anticipated in late 2026.”Trial data · SEC filing · Aug 6

What it means: the first look at a trial’s main results, as the company reports them.

Lead program: SRK-439 · Healthy · Phase 1
Its trial: Single- and Multiple-Ascending Dose Study of SRK-439 in Healthy AdultsPhase 1 · Recruiting · 76 people · main data estimated Dec 17, 2026 · NCT07444294

3 more trials, 41 filings, for Pro members.

Cash runway Jun 30 balance sheet

About 6 quarters

$492M in cash and short-term investments, at its spending over the last year

What it means: how long the cash would last at the same pace, before any new money. The company's estimate is “into 2027” (8-K, Jan 12). It has raised money since that balance sheet, which is not counted here.

For Pro members: the cash used each quarter, and the math.

Dilution on the horizon

Shelf registration (S-3ASR, filed Oct 7, 2024)
At-the-market share sales program (424B5, filed Aug 6, 2026)

For Pro members: 2 raises and their amounts, and the share count against a year ago.

Insiders

Director Srinivas Akkaraju bought 289,470 shares on Oct 26. 24 more insider trades this year.

From Form 4: open-market buys and sales only.

Get an alert when David Hallal buys or sells

For Pro members: every trade, and David Hallal’s 7 filings and quotes.

Get an alert when SRRK files news on its trialsSee it live, free until Wednesday morning. No account. No card. Then keep going with a free account.

See every upcoming FDA date →

FDA dates in the next 60 days

Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.

DateStockDrug

In 20 daysFDA decisionIn 20 days · FDA decisionCAPRCapricor TherapeuticsDeramiocelCAPRCapricor Therapeutics · $385MDeramiocelFDA decision due (PDUFA)
In 20 daysFDA decisionIn 20 days · FDA decisionSVRASavaraMolgramostimSVRASavara · $1.0BMolgramostimFDA decision due (PDUFA)
In 50 daysFDA decisionIn 50 days · FDA decisionMLYSMineralys TherapeuticsLorundrostatMLYSMineralys Therapeutics · $1.9BLorundrostatFDA decision due (PDUFA)

11 more FDA dates and 102 trial data dates in the next 60 days, each on the FDA calendar. Pro members see whether each company's cash lasts past its date, with an optional alert before it. See all 143 dates, ranked →

Why SRRK scores 0

Below Averagefor quality, not price, 1 of 14 chart checks firingWhat the Quality Score means

+1Chart checks 1 of 14 firing right now, one point each
+3Insider trades Srinivas Akkaraju (Director) bought $2M on Oct 26, and 5 more filings

Long-term trend subtracts
Profit subtractsRead on the last four quarters against the four before, or the last full year where no quarters are filed.
Dilution subtractsNew shares over the year: -1 at 10% more, -2 at 25% more.
Cash flow subtracts-1 when free cash flow over the last four quarters is negative.

No effect today: Run-up, Size, Growth, Volatility, Persistence, and News.

What every line is worth, and the reason behind it, on SRRK and every other stock.Get in free →

Price, score, chart checks, and the industry rank are from a snapshot taken at 6:57 PM ET, at least 15 minutes behind. How we rank stocks.

Tested. Our top-⁠scored stocks returned 2.2x the average stock over the next month. How we tested it

Alert me when SRRK's Quality Score turns up

See it live, free until Wednesday morning. No account. No card. Then keep going with a free account.

Here is what Pro members see.

The same page for Pro members, on AMD
Its Quality Score and rank, the line that drives it, and the live price.
The full chart
A year of candles to start, out to the whole history, with insider trades marked and the Quality Score under the price.
Every line of the score
Price action, the company, and signals, each with its points, on SRRK and every other stock.
FDA dates, counted down
Each date in the company's words, its cash against the date, and an optional alert before it.
CEOs buying their own stock
Every CEO buy, biggest names first. Sort, filter, save the list, and set optional alerts.
Congress trades
A member's trades, newest first, each with its amount. Sort and filter the whole list.
14 chart checks, read for you
The ones firing on the stock, each in plain words, its rule a tap away.
Earnings, week by week
Who reports each day, and how each stock took its last four reports.
The market map
Every stock a box, colored by its Quality Score.
Themes, ranked live
Each theme's stocks ranked by Quality Score, live. Here, AI chips.
The top 10, every day
The ten highest Quality Scores at each close, kept day by day, week by week.
Optional alerts, your way
Pick a stock, a score, a price, a filing, or a whole scan. It tells you by push or email.
Your watchlist, scored
Your stocks by Quality Score, today's move, or name.
On your phone and your laptop
The same account and watchlist on both, each laid out for its screen.

Prices refresh every 2.5 seconds during market hours.
Optional alerts by push, email, or the bell.
Add it to your Home Screen and it opens like an app.

SRRK has 1 of 14 chart checks firing

Trend1 of 5 shown

MA FAN 21 EMA W.EMA HH/HL 52W HI

Volume1 of 3 shown

VOL VDU U/D VOL

Tight range1 of 3 shown

ATR SQZ SQUEEZE NR7

Buying1 of 3 shown

OBV+CLOSE HI SPRING

The other 10 checks on SRRK, and all 14 on every stock.Get in free →

SRRK RSI today: 45.3, below its 50-day and 200-day averages

Not scored

Not in the Quality Score: over 20 years of tests, 2006 to 2026, they added no edge.

RSI 1445.3
Above 30, below 50.
MACD (12, 26, 9)Above signal
Crossed above its signal line 8 sessions ago.
50-day average$48.20
The price is 11.0% below it.
200-day average$48.19
The price is 11.0% below it.
50/200 crossGolden cross
The 50-day crossed above the 200-day on Nov 26, 2025.
ADX 1426.3
25 or more, with +DI above -DI.
Support$42.87
Swing low from Jan 28, 0.1% below the price.
Resistance$46.38
Swing high from Dec 23, 2025, 8.1% above the price.
52-week high$61.76
From Aug 26, 43.9% above the price.
52-week low$27.07
From Nov 7, 2025, 36.9% below the price.
Chart patternNone
No triangle, channel, or wedge in the last year.
Bollinger Bands (20, 2)Inside
The bands run from $39.45 to $44.36.
Volume0.5x
Against its 20-day average, for the time of day.

The deep dive on SRRK

What it does and how it makes money3 findings"Our proprietary platform is covered by a robust IP portfolio projected to expire well into the 2030s, excluding any patent term adjustments or extensions." (10-K for fiscal 2025)SEC filing · Mar 3, 2026
Where it stands2 findingsFor Pro members2 findings on where SRRK stands: its cash, debt, and share count, for Pro members
Who holds and trades it2 findingsInsiders bought $12.0M of shares on the open market in 90 days, with no sales; the largest, director Srinivas Akkaraju, bought $4.08M on Oct 26, 2026.Form 4, filed Oct 27, 2026
Against its closest peers4 peersNet income over four quarters: SRRK -$409M, NBIX $706M, HALO $414M, VCEL $24.2M.

5 more findings on SRRK, each with its source, for Pro membersGet in free →

How SRRK ranks in Biotech

SRRK is #124 of 291 by Quality Score.

How SRRK ranks in Biotech
1	KNSAKiniksa Pharmaceuticals International	6/14	21
2	TGTXTG Therapeutics	8/14	19
3	AMGNAmgen	5/14	19
	SPRYARS Pharmaceuticals		Open for its score
	SRPTSarepta Therapeutics		Open for its score
	STOKStoke Therapeutics		Open for its score
	STROSutro Biopharma		Open for its score
124	SRRKScholar Rock	1/14	0

Net income over four quarters: SRRK -$409M, NBIX $706M, HALO $414M, VCEL $24.2M.

When does SRRK report earnings, and what happens after?

Reports Tue Nov 10, before the open (in 8 days). Confirmed.

What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.

+1.9%-1.4%+10.0%

Mar 3May 7Aug 6

Reported	When	Gap	Reaction	5 sessions
Aug 6, 2026Before open	Before open	+4.9%	+10.0%	+12.4%
May 7, 2026Before open	Before open	+6.0%	-1.4%	+6.5%
Mar 3, 2026Before open	Before open	+4.1%	+1.9%	+1.7%

SRRK closed higher after 3 of its last 4 reports.

All 4 reports, and SRRK's Quality Score going into each

Everyone reporting earnings next week

SRRK sales and profit by year

Sales and profit by year

Sales grew in two of the last three years, to $33.2M in 2022. It lost money in each of the five years.

SRRK share count over time

16% more shares than a year earlier.

Weighted shares, quarter to Jun 30, 2026, both from one filing

Shares of SRRK outstanding, as filed
Shares outstanding	As of
121.8M	Aug 3, 2026
119.8M	May 4, 2026
114.9M	Feb 26, 2026
102M	Nov 5, 2025

Offerings, shelves, and splits of SRRK, from its filings
From its filings	Filed
Set up an at-the-market program for up to $200M of shares, about 4% of its market value	Aug 6, 2026
Raised $290M in a sale of shares, about 5% of its market value	Oct 9, 2024
Registered shares for a later sale (S-3ASR)	Oct 7, 2024

Insiders trading SRRK

SRRK insider trades

One insider bought $12M across 6 filings in the last 6 months. No open-⁠market sales on record. The newest:

BuySrinivas Akkaraju$4.1MDirectorat $41.59 on Oct 26, filed Oct 27

BuySrinivas AkkarajuDirector$4.1Mat $41.59 on Oct 26, filed Oct 27

All 6 insider filings on SRRK from the last six months, for Pro members.Get in free →

All SRRK insider trades

SRRK's officers and directors

Officers and directors with a Form 4 in the last 12 months.

David HallalChief Executive Officer · 2 trades
Vikas SinhaChief Financial Officer · 2 trades
Mo QatananiChief Scientific Officer · 6 trades
Akshay VaishnawPresident of R&D · 2 trades
Caryn ParlavecchioCHRO · 2 trades
Jing L. MarantzChief Medical Officer · 2 trades
Junlin HoGeneral Counsel · 2 trades
Keith WoodsChief Operating Officer · 2 trades

7 more officers and directors file at SRRK. Each page above names the rest.

See insider trades by person

Which ETFs hold SRRK?

In ETFs: SRRK is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.

About Scholar Rock Holding

Scholar Rock Holding Corp is a biopharmaceutical company focused on improving the lives of children and adults with Spinal Muscular Atrophy and other rare, severe, and debilitating neuromuscular diseases. Its pipeline candidates include apitegromab and a subcutaneous formulation of apitegromab. The clinical-stage pipeline also includes SRK-439, an investigational subcutaneously administered fully human anti-pro/latent myostatin antibody with high inhibitory potency and selectivity toward myostatin, being developed for the treatment of rare neuromuscular diseases. The company also maintains early-stage programs focused on therapies for rare, severe, and debilitating neuromuscular diseases.

289 employeesCambridge, MAscholarrock.com

SRRK's score card

Scholar Rock Holding (SRRK): Quality Score 0, Below Average, #124 of 291 in Biotech, with its price, on Breakaway — The picture a link to this page shows when it is shared.

Pro members see every line of every stock's score.

What would turn SRRK's score around: 7 things
4 more filings explained, a plain line each
Real-⁠time prices, no delay

BreakawayOct 27Srinivas Akkaraju bought SRRK$4.1M at $41.59, filed Oct 27

Alerts are optional.

See SRRK's 14 chart checks

See it live, free until Wednesday morning. No account. No card. Then keep going with a free account.

Straight Answers

As of Nov 2, 2026: SRRK's Quality Score is 0 (Below Average), #124 of 291 in Biotech. Insiders bought $12M in the last 6 months (Form 4).

Is SRRK a good stock to buy? What its Quality Score says

SRRK scores 0 today, which Breakaway calls Below Average. It is #124 of 291 in Biotech by Quality Score, with 1 of 14 chart checks firing. Up 281% over three years while the S&P 500 rose 89%. Cash lasts about 6 quarters at its spending (to Jun 30). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.

What is SRRK's Quality Score?

SRRK scores 0 today, which Breakaway calls Below Average (0 to 5). That is #124 of 291 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind SRRK's 0.

Are insiders buying SRRK?

One insider bought $12M across 6 filings in the last 6 months. No open-⁠market sales on record. The newest is Srinivas Akkaraju, Director, who bought $4.1M on Oct 26. Every filing, with the scored weight, for Pro members.

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.